Ajay Kumar Nooka, MD, MPH, FACP, highlights the significance of the FDA approval of elranatamab for select patients with relapsed/refractory multiple myeloma and expands the agent’s role in the expanding field of T cell–redirecting therapies approved for the treatment this patient population.
Treatment with elranatamab monotherapy produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma who received a prior BCMA-directed therapy, according to a pooled analysis of the MagnetisMM-1, MagnetisMM-2, MagnetisMM-3, and MagnetisMM-9 trials.